Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 5Recurrence 4Burkitt Lymphoma 4Neoplasm, Residual 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Stomach Neoplasms 1Solid Tumors 1Simpson-Golabi-Behmel syndrome 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Platinum-Resistant Ovarian Carcinoma 1Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 37Rituximab 31fludarabine phosphate 26Filgrastim 20ibrutinib 19Bortezomib 19fludarabine 17Peripheral Blood Stem Cell Transplantation 15Lenalidomide 15Bendamustine Hydrochloride 14Etoposide 12Cytarabine 9aldesleukin 7Vorinostat 7Tacrolimus 7Radiotherapy 7Prednisone 7Paclitaxel 7Melphalan 7Cyclosporine 7Biopsy 7venetoclax 6tanespimycin 6sargramostim 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Carmustine 6Vincristine 5Specimen Handling 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Mantle-Cell × Immunotherapy, Adoptive × Clear all
NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1 Recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡